Programs & Research
Everyone said brain health disorders were too tough to tackle. We said they are too important not to.
Sage stepped up to fill an innovation void by thinking differently about brain health disorders and how we approach the discovery and development of new medicines.
Sage is developing novel drug candidates with the potential to transform the lives of people with brain health disorders. Our proprietary compounds are intended to modulate GABA or NMDA receptor activity and are being studied for their therapeutic potential in restoring balance in the brain.
At Sage, we:
- think differently about brain health disorders and how we approach the discovery and development of new medicines.
- search for solutions that have the potential to work faster and last longer, to radically—not just incrementally—improve the lives of patients and their families.
- leverage our distinct approach to translational medicines and science to drive efficiency in our drug development approach.
We believe our focused, practical and deliberate approach to drug development provides the opportunity to develop potentially transformative medicines that we hope will achieve our mission: pioneer solutions to deliver life-changing brain health medicines, so every person can thrive.
Sage has a robust portfolio of drug candidates being developed for disorders of the brain. Our proprietary compounds target the GABA and NMDA receptor systems. Dysfunction in these systems is known to be at the core of numerous disorders.
Translational data drive efficiency in our drug development approach
We use a translational research strategy to explore the activity of our compounds, and their potential in the treatment of disorders of the brain. Our distinct approach begins by conducting small clinical studies to evaluate activity and methodology. We measure biomarkers—from electrical activity to functional brain imaging—to gain insight into how brain cells are communicating with each other. These tools help us understand targets in context – and then inform the design of later stage clinical trials in well-defined patient populations.
Our latest product, ZURZUVAE™ (zuranolone) CIV, in collaboration with Biogen, is now available as the first and only oral, 14-day treatment for adults with postpartum depression.